Suppression of bladder hyperreflexia by intravesical resiniferatoxin

Cruz, Francisco; Guimarães, M.; Silva, Carlos; Reis, Mário

doi:10.1016/s0140-6736(05)63330-2

Cited by 161 publications

(94 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experimentally, several lines of evidence support a central role for SP and the neurokinin-1 receptor (NK1; the primary receptor for SP) as mediators of bladder inflammation. SP has been implicated in both neurogenic inflammation (1,4,7,50) and experimental cystitis (7,11,13). In addition, NK1 receptor antagonists have been shown to reduce experimental inflammation (2-3, 29, 31).…”

mentioning

confidence: 99%

LPS-sensory peptide communication in experimental cystitis

Saban

Hammond

et al. 2002

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

Stimulation of sensory nerves can lead to release of peptides such as substance P (SP) and consequently to neurogenic inflammation. We studied the role of bacterial lipopolysaccharide (LPS) in regulating SP-induced inflammation. Experimental cystitis was induced in female mice by intravesical instillation of SP, LPS, or fluorescein-labeled LPS. Uptake of fluorescein-labeled LPS was determined by confocal analysis, and bladder inflammation was determined by morphological analysis. SP was infused into the bladders of some mice 24 h after exposure to LPS. In vitro studies determined the capacity of LPS and SP to induce histamine and cytokine release by the bladder. LPS was taken up by urothelial cells and distributed systemically. Twenty-four hours after instillation of LPS or SP, bladder inflammation was characterized by edema and leukocytic infiltration of the bladder wall. LPS pretreatment enhanced neutrophil infiltration induced by SP, increased in vitro release of histamine, tumor necrosis factor-α, and interferon-γ, and significantly reduced transforming growth factor-β1 release. These findings suggest that LPS amplifies neurogenic inflammation, thereby playing a role in the pathogenesis of neurogenic cystitis.

show abstract

mentioning

confidence: 99%

LPS-sensory peptide communication in experimental cystitis

Saban

Hammond

et al. 2002

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…A measure of 100 ml of resiniferatoxin (Sigma, St Louis, MO, USA) solution, at a concentration of 100 nM, was diluted in 10% ethanol. 9,18 This solution was prepared immediately before each instillation to decrease contact of the resiniferatoxin with the plastic container. It was then instilled into the bladder at an infusion rate of 30 ml/min, without anesthesia, after catheterization with a 16 F Foley catheter and evacuation of residual urine, and left in place for 30 min with Foley clamping.…”

Section: Methodsmentioning

confidence: 99%

“…3,4 However, some patients cannot be controlled by oral medications, despite maximal dosages, and some cannot tolerate the side effects, 5,6 such as a dry mouth, visual disturbance or constipation, at any dosage. Recently, to minimize the side effects of anticholinergics, intravesical instillations, such as oxybutynin 7,8 or vanilloids, 9 have been tried. Of these, vanilloids, unmyelinated C-fiber blockers (capsaicin or resiniferatoxin), have been tried, but the effects of the treatment are equivocal.…”

Section: Introductionmentioning

confidence: 99%

Effect of the intravesical resiniferatoxin instillation evaluated by the ice provocative urodynamic study

et al. 2005

View full text Add to dashboard Cite

Study design: Prospective urodynamic investigation before and after intravesical resiniferatoxin instillation treatment. Objective: To evaluate the effectiveness of intravesical resiniferatoxin instillation for the treatment of neurogenic detrusor overactivity (NDO), using conventional and ice provocative urodynamic studies to monitor the activity of the unmyelinated C-fiber. Setting: Spinal Cord Injury Unit, Yonsei Rehabilitation Hospital, Seoul, Korea. Methods: A measure of 100 ml of resiniferatoxin solution, at a concentration of 100 nM diluted in 10% ethanol, was intravesically instilled into the bladder of 15 spinal cord injury patients with NDO. Conventional and ice provocative urodynamic studies were performed to evaluate the change in the involuntary detrusor activity, reflex volume, maximal bladder capacity, compliance, maximal detrusor pressure and reflex volume ratio 7 days before and 30 days after the instillation. Results: Before the intravesical resiniferatoxin instillation, all patients exhibited NDO in both the conventional and ice provocative urodynamic studies, with a mean reflex volume ratio of 0.4570.22. There was no significant change in the maximal bladder capacity, compliance and maximal detrusor pressure at the follow-up urodynamic study, but the reflex volume ratio was significantly increased (Po0.05) after the intravesical resiniferatoxin instillation. Among the 15 patients, three (20%) showed complete and nine (60%) partial suppression of the unmyelinated C-fiber activities. Conclusion: Intravesical resiniferatoxin instillation was partially controlled by the unmyelinated C-fiber activities, which were estimated by an ice provocative urodynamic study. Therefore, further studies on the optimal dosage and accurate indications for resiniferatoxin instillation are required.

show abstract

“…Auto-augmentation enterocystoplasty and ileal conduit are complicated surgical interventions and are considered as the last option. Intravesical capsaicin and resiniferatoxin are currently in the evaluation phase, and research needs to be improved in this regard (18,29).…”

Section: -Neurogenic Detrusor Overactivitymentioning

confidence: 99%

Use of botulinum toxin in urology: a literature review

Bayrak¹,

Şeçkiner²,

Onur³

et al. 2018

Eur J Ther

View full text Add to dashboard Cite

Botulinum neurotoxin (BoNT) is currently preferred as a minimally invasive treatment for lower urinary tract pathologies. Although BoNT injections have become widespread globally for the past 5 years, today, the urological use of BoNT Type A (BoNT-A) is only licensed for the treatment of neurogenic detrusor overactivity and overactive bladder. Despite the relative evidence for the use of BoNT-A in benign prostatic enlargement, there is no high-level evidence data for the use in detrusor sphincter dyssynergia, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. In this comprehensive review, we mention the mechanism of action and efficacy of BoNT in various urological disorders, present the reliability, and evaluate the literature data supporting its use.

show abstract

Suppression of bladder hyperreflexia by intravesical resiniferatoxin

Cited by 161 publications

References 5 publications

LPS-sensory peptide communication in experimental cystitis

LPS-sensory peptide communication in experimental cystitis

Effect of the intravesical resiniferatoxin instillation evaluated by the ice provocative urodynamic study

Use of botulinum toxin in urology: a literature review

Contact Info

Product

Resources

About